blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3056200

EP3056200 - HUPERZINE FOR USE IN TREATING SEIZURE [Right-click to bookmark this link]
Former [2016/33]HUPERZINE FOR USE IN TREATING SEIZURE, PAIN, ORTHOSTATIC HYPOTENSION OR VERTIGO
[2023/29]
StatusNo opposition filed within time limit
Status updated on  12.07.2024
Database last updated on 12.07.2024
FormerThe patent has been granted
Status updated on  04.08.2023
FormerGrant of patent is intended
Status updated on  27.06.2023
FormerExamination is in progress
Status updated on  18.01.2019
FormerRequest for examination was made
Status updated on  15.06.2017
Most recent event   Tooltip12.07.2024Lapse of the patent in a contracting state
New state(s): DK		published on 14.08.2024 [2024/33]
12.07.2024No opposition filed within time limitpublished on 14.08.2024 [2024/33]
Applicant(s)For all designated states
President and Fellows of Harvard College
17 Quincy Street
Cambridge, MA 02138 / US
[2016/33]
Inventor(s)01 / Schachter, Steven, C.
10 Pioneer Circle
Sharon, MA 02067 / US
 [2016/33]
Representative(s)Simmons & Simmons LLP (Munich), et al
Lehel Carré
Thierschplatz 6
80538 Munich / DE
[N/P]
Former [2023/36]Lahrtz, Fritz, et al
Simmons & Simmons LLP
Lehel Carré Thierschplatz 6
80538 München / DE
Former [2016/33]Lahrtz, Fritz
Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68
81675 München / DE
Application number, filing date16000741.523.05.2006
[2016/33]
Priority number, dateUS20050683745P23.05.2005         Original published format: US 683745 P
US20060756141P04.01.2006         Original published format: US 756141 P
[2016/33]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP3056200
Date:17.08.2016
Language:EN
[2016/33]
Type: A3 Search report 
No.:EP3056200
Date:30.11.2016
Language:EN
[2016/48]
Type: B1 Patent specification 
No.:EP3056200
Date:06.09.2023
Language:EN
[2023/36]
Search report(s)(Supplementary) European search report - dispatched on:EP31.10.2016
ClassificationIPC:A61K31/215, A61K31/74, A61K9/20, A61P25/08, A61P25/00, A61P29/00, A61P19/02, A61P25/02, A61K31/473, A61K31/4745
[2023/29]
CPC:
A61K9/0019 (EP,US); A61K31/215 (EP,US); A61K31/473 (EP,US);
A61K31/4745 (EP,US); A61K31/74 (EP,US); A61P19/02 (EP);
A61P25/00 (EP); A61P25/02 (EP); A61P25/08 (EP);
A61P29/00 (EP); A61K9/0024 (EP,US) (-)
Former IPC [2016/33]A61K31/215, A61K31/74, A61K9/20, A61P25/08, A61P25/00, A61P29/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/28]
Former [2016/33]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:HUPERZIN ZUR VERWENDUNG IN DER BEHANDLUNG VON EINEM ANFALL[2023/29]
English:HUPERZINE FOR USE IN TREATING SEIZURE[2023/29]
French:HUPERZINE POUR SON UTILISATION DANS LE TRAITEMENT D'UNE ATTAQUE[2023/29]
Former [2016/33]HUPERZIN ZUR VERWENDUNG IN DER BEHANDLUNG VON EINEM ANFALL, SCHMERZ, ARTERIELLER HYPOTONIE ODER VERTIGO
Former [2016/33]HUPERZINE FOR USE IN TREATING SEIZURE, PAIN, ORTHOSTATIC HYPOTENSION OR VERTIGO
Former [2016/33]HUPERZINE POUR SON UTILISATION DANS LE TRAITEMENT D'UNE ATTAQUE, DE LA DOULEUR, DE L'HYPOTENSION ORHTOSTATIQUE OU DES VERTIGES
Examination procedure30.03.2016Date on which the examining division has become responsible
30.05.2017Amendment by applicant (claims and/or description)
30.05.2017Examination requested  [2017/28]
18.01.2019Despatch of a communication from the examining division (Time limit: M06)
22.08.2019Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
31.10.2019Reply to a communication from the examining division
15.04.2020Despatch of a communication from the examining division (Time limit: M08)
22.12.2020Reply to a communication from the examining division
17.10.2022Despatch of a communication from the examining division (Time limit: M04)
06.02.2023Reply to a communication from the examining division
30.03.2023Despatch of a communication from the examining division (Time limit: M04)
23.05.2023Reply to a communication from the examining division
28.06.2023Communication of intention to grant the patent
26.07.2023Fee for grant paid
26.07.2023Fee for publishing/printing paid
26.07.2023Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP06770999.8  / EP1901733
Opposition(s)07.06.2024No opposition filed within time limit [2024/33]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
31.10.2019Request for further processing filed
31.10.2019Full payment received (date of receipt of payment)
Request granted
15.11.2019Decision despatched
Fees paidRenewal fee
30.03.2016Renewal fee patent year 03
30.03.2016Renewal fee patent year 04
30.03.2016Renewal fee patent year 05
30.03.2016Renewal fee patent year 06
30.03.2016Renewal fee patent year 07
30.03.2016Renewal fee patent year 08
30.03.2016Renewal fee patent year 09
30.03.2016Renewal fee patent year 10
30.03.2016Renewal fee patent year 11
30.05.2017Renewal fee patent year 12
29.05.2018Renewal fee patent year 13
28.05.2019Renewal fee patent year 14
27.05.2020Renewal fee patent year 15
27.05.2021Renewal fee patent year 16
27.05.2022Renewal fee patent year 17
30.05.2023Renewal fee patent year 18
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT06.09.2023
CZ06.09.2023
DK06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
IT06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
PL06.09.2023
RO06.09.2023
SE06.09.2023
SK06.09.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
[2024/33]
Former [2024/26]AT06.09.2023
CZ06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
IT06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
PL06.09.2023
RO06.09.2023
SE06.09.2023
SK06.09.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
Former [2024/25]AT06.09.2023
CZ06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
PL06.09.2023
RO06.09.2023
SE06.09.2023
SK06.09.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
Former [2024/23]AT06.09.2023
CZ06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
RO06.09.2023
SE06.09.2023
SK06.09.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
Former [2024/21]FI06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
SE06.09.2023
GR07.12.2023
IS06.01.2024
Former [2024/14]FI06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
SE06.09.2023
GR07.12.2023
Former [2024/10]FI06.09.2023
LT06.09.2023
LV06.09.2023
SE06.09.2023
GR07.12.2023
Former [2024/09]FI06.09.2023
LT06.09.2023
SE06.09.2023
GR07.12.2023
Former [2024/08]LT06.09.2023
GR07.12.2023
Documents cited:Search[X]WO0132115  (XEL HERBACEUTICALS [US]) [X] 1-7,13-15 * claims 1-30 * * page 16, lines 6-13 * * page 3, line 3 - page 4, line 7 *;
 [XY]WO0211712  (UNIV GEORGETOWN [US]) [X] 1-7,13-15 * page 16, line 27 - page 21, line 9 * * page 22, lines 4-5 * * page 24 - page 28; example point 6 * [Y] 5;
 [XYI]  - TONDULI L S ET AL, "Effects of huperzine used as pre-treatment against soman-induced seizures", NEUROTOXICOLOGY (LITTLE ROCK), (200102), vol. 22, no. 1, ISSN 0161-813X, pages 29 - 37, XP002632202 [X] 1-4,6,7,13-15 * abstract * * page 36, paragraph conclusion * * page 35, paragraph first after the heading discussion * [Y] 5 [I] 5
 [XYI]  - LALLEMENT G ET AL, "EFFICACY OF HUPERZINE IN PREVENTING SOMAN-INDUCED SEIZURES, NEUROPATHOLOGICAL CHANGES AND LETHALITY", FUNDAMENTAL & CLINICAL PHARMACOLOGY, ELSEVIER, PARIS, FR, (19970101), vol. 11, no. 5, ISSN 0767-3981, pages 387 - 394, XP001106911 [X] 1-4,6,7,13-15 * abstract * * discussion; pages 392-393 * [Y] 5 [I] 5
 [XI]  - GALEOTTI, NICOLETTA ET AL, "Antinociceptive profile of the natural cholinesterase inhibitor huperzine A", DRUG DEVELOPMENT RESEARCH , 54(1), 19-26 CODEN: DDREDK; ISSN: 0272-4391, (2001), XP002632199 [X] 1-4,6,7,13-15 * abstract * * results - antinociceptive activity of huperzine A; page 21 * [I] 5
 [T]  - COLEMAN B R ET AL, "[+]-Huperzine A treatment protects against N-methyl-d-aspartate-induced seizure/status epilepticus in rats", CHEMICO-BIOLOGICAL INTERACTIONS, ELSEVIER SCIENCE IRLAND, IR, vol. 175, no. 1-3, doi:10.1016/J.CBI.2008.05.023, ISSN 0009-2797, (20080925), pages 387 - 395, (20080523), XP024530567 [T] 1-7,13-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.cbi.2008.05.023
by applicantUS4776353
 US4839174
 US4848376
 US4908213
 US4907606
 US4929731
 US4943435
 US4967773
 US5004610
 US5035252
 US5104880
 US5106979
 US5147654
 US5177082
 US5230896
 US5293883
 US5326563
 US5364630
 US5411739
 USD358683S
 US5547960
 US5549906
 US5603947
 US5633008
 US5663344
 US5662920
 US5716635
 US5725876
 US5799633
 US5869672
 US5929084
 US5939100
 US6083962
    - MELZACK, R., PAIN, (1975), vol. 1, pages 277 - 299
    - WRIGHT ET AL., EUR. J. PAIN, (2001), vol. 5, pages 279 - 284
    - BIERI ET AL., PAIN, (1990), vol. 41, pages 139 - 150
    - KUTTNER ET AL., CAN. J. BEHAV. SCI., (1989), vol. 21, pages 198 - 209
    - PEYRON ET AL., J. RHEUMATOL., (1993), vol. 20, no. 39, pages 10 - 15
    - MCKHANN ET AL., NEUROLOGY, (1984), vol. 34, pages 939 - 944
    - HUNSKAAR, S.; O. B. FASMER; K. HOLE, J. NEUROSCI. METHODS, (1985), vol. 14, pages 69 - 76
    - Saunders Manual of Neurologic Practice, pages 244 - 255
    - Office Practice of Neurology, CHURCHILL, LIVINGSTON PRESS, pages 928 - 937
    - SARKISIAN, EPILEPSY AND BEHAVIOR, (2001), vol. 2, pages 201 - 216
    - WADA, EPILEPSIA, (1974), vol. 19, pages 217 - 227
    - SATO ET AL., EPILEPSY RESEARCH, (1990), vol. 5, pages 117 - 124
    - SILVER ET AL., ANN. NEURAL., (1991), vol. 29, pages 356 - 363
    - GODDARD ET AL., EXP. NEUROL., (1969), vol. 25, pages 295 - 330
    - WHITE ET AL., Antiepileptic Drugs, 5th edition,, LIPPINCOTT WILLIAMS & WILKINS, (2002), pages 36 - 48
    - BARTON ET AL., EPILEPSY RES., (2001), vol. 47, pages 217 - 227
    - CAHN ET AL., ANGEW. CHEM. INTER. EDIT., (1966), vol. 5, page 385
    - CAHN ET AL., ANGEW. CHEM., (1966), vol. 78, page 413
    - CAHN; INGOLD, J. CHEM. SOC., (1951), page 612
    - CAHN ET AL., EXPERIENTIA, (1956), vol. 12, page 81
    - CAHN, J., CHERN. EDUC, (1964), vol. 41, page 116
    - LIU ET AL., CAN. J. CHEM., (1986), vol. 64, page 837
    - AYER ET AL., CAN. J. CHEM., (1989), vol. 67, page 1077
    - AYER ET AL., CAN. JCHEM., (1989), vol. 67, page 1548
    - J. LIU ET AL., CAN. J. CHEM., (1986), vol. 64, pages 837 - 839
    - MA ET AL., ANN NY ACAD SCI., (1998), vol. 854, pages 506 - 7
    - MA ET AL., N-SARCH PHARMACOL, (1998), vol. 358, no. 1, page 53194
    - JIANG H ET AL., MEDICINAL CHEMISTRY, (2003), vol. 10, pages 2231 - 2252
    - RAJENDRAN ET AL., BIOORG. MED CHEM LETT., (2002), vol. 12, pages 1521 - 1523
    - WANG ET AL., NEUROSCIENCE LETTERS, (1999), vol. 272, pages 21 - 24
    - YAN ET AL., ACTA PHARMACOL. SIN, (1987), vol. 8, page 117
    - BRUFANI ET AL., Alzheimer Disease: From Molecular Biology to Therapy, (1996), pages 171 - 177
    - SCHMIDT ET AL., Alzheimer Disease: From Molecular Biology to Therapy, (1996), pages 217 - 221
    - VARGAS ET AL., Alzheimer Disease: From Molecular Biology to Therapy, (1996), pages 251 - 255
    - GREIG ET AL., Alzheimer Disease: From Molecular Biology to Therapy, (1996), pages 231 - 237
    - GIACOBINI ET AL., Alzheimer Disease: From Molecular Biology to Therapy, (1996), pages 187 - 204
    - SALTER, J. OROFAC PAIN, (2004), vol. 18, pages 318 - 24
    - EBERT, BIOCHEM PHARMACOL., (1998), vol. 56, pages 553 - 9
    - MAX, NEUROPATHIC PAIN SYNDROMES, ADVANCES IN PAIN RESEARCH AND THERAPY, (1991), page 18
    - WARD ET AL., TETRAHEDRON LETTERS, (2006), vol. 47, pages 553 - 556
    - MA ET AL., NAT. PROD. REP., (2004), vol. 21, pages 752 - 772
    - ZHOU ET AL., NEUROSCIENCE LETTERS, (2004), vol. 313, pages 137 - 140
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.